PROCEPT BioRobotics® Announces New Clinical and Real-World Data Highlighting Effectiveness, Durability, Superior Safety and Reproducibility of Aquablation® Therapy for BPH
REDWOOD SHORES, Calif.--(BUSINESS WIRE)--May 20, 2019--
New clinical data presented at the American Urological Association (AUA) Annual Meeting confirmed that PROCEPT BioRobotics ’ Aquablation therapy is a durable, safe, effective and reproducible minimally invasive surgical treatment option for benign prostatic hyperplasia (BPH). Longer-term data from controlled FDA pivotal studies demonstrated durability of Aquablation therapy in a broad range of prostate sizes, while real-world experience from Germany in non-selected patients confirmed reproducibility and yielded results consistent with the pivotal studies. With no restriction on prostate size, Aquablation therapy with the AQUABEAM ® Robotic System is the only FDA-cleared autonomous robot for surgery.
“These longer-term study results, and the recent addition of Aquablation therapy to the AUA surgical practice guidelines for BPH, position Aquablation therapy as a new standard of care for patients suffering from BPH,” said Nikolai Aljuri, Ph.D., PROCEPT BioRobotics president and chief executive officer. “Aquablation therapy is the only BPH treatment that democratizes BPH surgery by delivering predictable and reproducible outcomes from day one, independent of prostate anatomy, size or complexity – and it does so regardless of surgeon experience.”
About PROCEPT BioRobotics
Based in Silicon Valley, PROCEPT BioRobotics is a privately-held surgical robotics company enabling better patient care by developing transformative solutions in urology. The company offers the world’s first commercially available minimally invasive surgical robot providing autonomous tissue removal to safely and effectively treat BPH. Aquablation therapy, delivered by the AQUABEAM Robotic System, combines the clarity of real-time, multi-dimensional imaging, autonomous robotics and heat-free waterjet ablation for targeted, controlled, and immediate removal of prostate tissue for the treatment of lower urinary tract symptoms (LUTS) caused by BPH. For more information, visit http://www.PROCEPT-BioRobotics.com.
Prof. Thorsten Bach is a paid consultant of PROCEPT BioRobotics Corporation.
Important Safety Information: All surgical treatments have inherent and associated side effects. The most common side effects are mild and transient, and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. For more information about potential side effects and risks associated with Aquablation therapy, speak with your urologist or surgeon. No claim is made that the AQUABEAM Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190520005242/en/
CONTACT: Diana Soltesz
Nobles Global Communications
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: SURGERY HEALTH CLINICAL TRIALS HOSPITALS MEDICAL DEVICES FDA CONSUMER MEN
SOURCE: PROCEPT BioRobotics
Copyright Business Wire 2019.
PUB: 05/20/2019 07:00 AM/DISC: 05/20/2019 07:01 AM